Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

DATA COMPILATION
#PharmaFlow

Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

Stock Recap
#PipelineProspector

Olux E

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

68 API Suppliers, 14 USDMF, 12 CEP/COS, 4 JDMF, 14 EU WC, 16 KDMF, 14 NDC API, 39 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

44 Drugs in Development

44 Drugs in Development

FINISHED DOSAGE FORMULATIONS

267 FDF Dossiers, 100 FDA Orange Book, 94 Europe, 25 Canada, 3 Australia, 9 South Africa, 36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CREAM;TOPICAL - 0.025%, AEROSOL, FOAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, LOTION;TOPICAL - 0.05%, LOTION;TOPICAL - 0.05%, SHAMPOO;TOPICAL - 0.05%, AEROSOL, FOAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 SPI Pharma, 1 Gangwal Healthcare, 8 Nanjing Well Pharmaceutical, 3 Kirsch Pharma, 4 Dr. Paul Lohmann GmbH & Co. KGaA, 1 ACG Worldwide, 9 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 2 CD Formulation, 1 Clariant, 14 Corel Pharma Chem, 1 Esteem Industries, 1 Finar, 9 Gangwal Chemicals, 2 Gloria Interchem, 3 Ideal Cures, 9 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 3 Microlex e.U, 1 Nanjing Bold Chemical, 1 Novo Excipients, 2 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

42 Topical, 38 Coating Systems & Additives, 23 Solubilizers, 17 Thickeners and Stabilizers, 16 Controlled & Modified Release, 16 Parenteral, 15 Emulsifying Agents, 13 Surfactant & Foaming Agents, 11 Film Formers & Plasticizers, 8 API Stability Enhancers, 6 Granulation, 5 Direct Compression, 5 Empty Capsules, 5 Taste Masking, 4 Rheology Modifiers, 4 Vegetarian Capsules, 4 Fillers, Diluents & Binders, 3 Lubricants & Glidants, 2 Co-Processed Excipients, 2 Coloring Agents, 1 Chewable & Orodispersible Aids, 1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

90 News #PharmaBuzz

90 News #PharmaBuzz

GLOBAL SALES INFORMATION

41 US Medicaid Prescriptions, 32 Regulatory FDF Prices

MARKET PLACE

26 APIs, 3 FDF Dossiers

PATENTS & EXCLUSIVITIES

17 US Patents, 1 US Exclusivities, 3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 JP, 4 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
31/03/2026	Symbiotec Pharmalab	India	Symbiotec Pharmalab Private Limited	229MF10086	Clobetasol propionate	2017-04-25	2020-10-05	385/2, Pigdamber, Off. A. B. Road, Rau, Indore 453331 (M.P.) India
31/03/2026	Axplora	Germany	Farmabios S. p. A.	222MF10130	Clobetasol propionate (for manufacturing purposes only)	2010-04-12	2019-04-09	Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Olux E

Olux E

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

68 API Suppliers

14 USDMF

12 CEP/COS

4 JDMF

14 EU WC

16 KDMF

14 NDC API

39 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

44 Drugs in Development

FINISHED DOSAGE FORMULATIONS

267 FDF Dossiers

100 FDA Orange Book

94 Europe

25 Canada

3 Australia

9 South Africa

36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CREAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CREAM;TOPICAL - 0.025%

AEROSOL, FOAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

LOTION;TOPICAL - 0.05%

LOTION;TOPICAL - 0.05%

SHAMPOO;TOPICAL - 0.05%

AEROSOL, FOAM;TOPICAL - 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 SPI Pharma

1 Gangwal Healthcare

8 Nanjing Well Pharmaceutical

3 Kirsch Pharma

4 Dr. Paul Lohmann GmbH & Co. KGaA

1 ACG Worldwide

9 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

17 BASF

2 CD Formulation

1 Clariant

14 Corel Pharma Chem

1 Esteem Industries

1 Finar

9 Gangwal Chemicals

2 Gloria Interchem

3 Ideal Cures

9 Kerry

3 Kima Chemical

6 Lonza Capsugel

5 Lubrizol Life Science Health

3 Microlex e.U

1 Nanjing Bold Chemical

1 Novo Excipients

2 Pluviaendo

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

18 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 The Dow Chemical Company

1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

42 Topical

38 Coating Systems & Additives

23 Solubilizers

17 Thickeners and Stabilizers

16 Controlled & Modified Release

16 Parenteral

15 Emulsifying Agents

13 Surfactant & Foaming Agents

11 Film Formers & Plasticizers

8 API Stability Enhancers

6 Granulation

5 Direct Compression

5 Empty Capsules

CREAM;TOPICAL - 0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AEROSOL, FOAM;TOPICAL - 0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

AEROSOL, FOAM;TOPICAL - 0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons